CVE-2022-30277BD Synapsys™ – Insufficient Session Expiration
Updated under an hour ago ()
Does this affect you?
It affects Becton Dickinson (BD) BD Synapsys™ and 1 other product. Add what you run to find out whether that includes you.
EPSS puts the chance of exploitation in the next 30 days at 0.23%, higher than 13% of scored CVEs.
Do this next
Free account, 1 product
BD Synapsys™, versions 4.20, 4.20 SR1, and 4.30, contain an insufficient session expiration vulnerability. If exploited, threat actors may be able to access, modify or delete sensitive information, including electronic protected health information (ePHI), protected health information (PHI) and personally identifiable information (PII).
- CVSS
- 5.7 MEDIUM (v3.1, CNA)CVSS:3.1/AV:P/AC:L/PR:L/UI:R/S:U/C:H/I:H/A:N
- Weakness (CWE)
- CWE-613
- Known exploited
- Not in CISA's KEV catalog
- EPSS (exploitation in the next 30 days)
- 0.23% (percentile 13)
- Assigned by
- BD
- NVD analysis
- Modified
- Record last updated
- Sep 16, 2024
- First seen by InfoSec Signals
- Oct 12, 2026
Affected products
Becton Dickinson (BD) BD Synapsys™ becton_dickinson_bd:bd_synapsystm (from the name) | from 4.20 through 4.30 | CNA record |
bd synapsys bd:synapsys | 4.20; 4.20; 4.30 | NVD |
References
- https://cybersecurity.bd.com/bulletins-and-patches/bd-synapsys-insufficient-session-expirationx-refsource-confirm, vendor-advisory
The CVE record on cve.org NVD's entry
The CVE record is authoritative. Products marked “from the name” were identified from the CNA's free-text names, not a CPE, and are matched less certainly. This product uses the NVD API but is not endorsed or certified by the NVD.